First Prostaglandin Analog with one of its Metabolites Being Nitric Oxide Approved to Provide Consistent and Sustained IOP Reduction Through 12 Months
LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE, Nov. 2, 2017 – Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A.
- Nicox to receive $6 million upfront payment and up to an additional $42.5 million in future milestones, plus 8-15% in tiered royalties
- Eyevance targeting U.S. launch of ZERVIATETM (cetirizine ophthalmic solution) 0.24% in late 2018
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company,
06/11/2017Nicox to Host Investor Conference Call on November 3. 2017. Follows the November 2. 2017 Approval of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% by the U.S. FDA
03/11/2017Nicox Highlights VYZULTA approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives